Using the Pharmaceutical Collection Database to identify patient adherence to oral hypoglycaemic medicines

Mangesh D. Kharjul; Claire Cameron; Rhiannon Braund

doi:10.1071/HC19017

RESEARCH ARTICLE (Open Access)

Previous Next Contents Vol 11(3)

Using the Pharmaceutical Collection Database to identify patient adherence to oral hypoglycaemic medicines

Mangesh D. Kharjul ¹ ⁴ , Claire Cameron ² , Rhiannon Braund ³

+ Author Affiliations

- Author Affiliations

¹ School of Pharmacy, University of Otago, Dunedin, New Zealand

² Dean’s Department, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

³ New Zealand Pharmacovigilance Centre, University of Otago, Dunedin, New Zealand

⁴ Corresponding author. Email: khama123@student.otago.ac.nz

Journal of Primary Health Care 11(3) 265-274 https://doi.org/10.1071/HC19017
Published: 30 September 2019

Journal Compilation © Royal New Zealand College of General Practitioners 2019 This is an open access article licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Abstract

INTRODUCTION: Poor adherence to oral hypoglycaemic medicines is a key contributor to therapy failure and sub-optimal glycaemic control among people with type 2 diabetes. It is unclear how commonly non-adherence to oral hypoglycaemics occurs in the general population. This information is essential to design and implement local adherence strategies.

AIM: This study aimed to determine levels of sub-optimal adherence and identify patient groups who may need additional adherence support.

METHODS: The dispensing data of 340,283 patients from one District Health Board was obtained from the Pharmaceutical Collection Database for the period 2008–15. Of these, 12,405 patients received oral hypoglycaemic therapy during the study period. The proportion of days covered (PDC) was calculated for patients with complete data and a PDC value of ≥80% was used to indicate sufficient adherence. Patient demographics (gender, ethnicity, age, socioeconomic status) and therapy type (mono- or combination) were described.

RESULTS: Overall, 54.5% of the patients were found to have a PDC of <80% and so were considered non-adherent. Non-adherence was significantly higher in patients receiving combination oral hypoglycaemic therapy than monotherapy; in male patients; in New Zealand Māori patients; and in patients with higher socioeconomic deprivation.

DISCUSSION: In the study region, non-adherence to oral hypoglycaemic medicines was significant and widespread. Identification of such patients is important so that strategies to enhance adherence can be implemented. Prescribers need to be encouraged to optimise monotherapy before the addition of another oral hypoglycaemic, and adherence support services should be offered not only to older patients.

KEYWORDS: Pharmaceutical Collection Database; oral hypoglycaemics; adherence

References

[1] World Health Organization. Global Report on Diabetes. Geneva: WHO; 2016. [Cited 2018 April 4]. Available from: http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf?sequence=1.

[2] Grant RW, Kirkman MS. Trends in the evidence level for the American Diabetes Association’s “Standards of Medical Care in Diabetes” from 2005 to 2014. Diabetes Care. 2015; 38 6–8.
| Trends in the evidence level for the American Diabetes Association’s “Standards of Medical Care in Diabetes” from 2005 to 2014.Crossref | GoogleScholarGoogle Scholar | 25538309PubMed |

[3] Zhang P, Gregg E. Global economic burden of diabetes and its implications. Lancet Diabetes Endocrinol. 2017; 5 404–5.
| Global economic burden of diabetes and its implications.Crossref | GoogleScholarGoogle Scholar | 28456417PubMed |

[4] Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015; 33 811–31.
| The economic costs of type 2 diabetes: a global systematic review.Crossref | GoogleScholarGoogle Scholar | 25787932PubMed |

[5] Seib C, Parkinson J, McDonald N, et al. Lifestyle interventions for improving health and health behaviours in women with type 2 diabetes: a systematic review of the literature 2011–2017. Maturitas. 2018; 111 1–14.
| Lifestyle interventions for improving health and health behaviours in women with type 2 diabetes: a systematic review of the literature 2011–2017.Crossref | GoogleScholarGoogle Scholar | 29673826PubMed |

[6] Thent ZC, Das S, Henry LJ. Role of exercise in the management of diabetes mellitus: the global scenario. PLoS One. 2013; 8 e80436
| Role of exercise in the management of diabetes mellitus: the global scenario.Crossref | GoogleScholarGoogle Scholar | 24236181PubMed |

[7] Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J Educ Health Promot. 2014; 3 1–8.
| The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern.Crossref | GoogleScholarGoogle Scholar | 24741641PubMed |

[8] Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015; 38 604–9.
| 25573883PubMed |

[9] Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic review. Diabet Med. 2015; 32 725–37.
| Adherence to diabetes medication: a systematic review.Crossref | GoogleScholarGoogle Scholar | 25440507PubMed |

[10] Zullig LL, Gellad WF, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015; 9 139–49.
| Improving diabetes medication adherence: successful, scalable interventions.Crossref | GoogleScholarGoogle Scholar | 25670885PubMed |

[11] Farmer AJ, Rodgers LR, Lonergan M, et al. Adherence to oral glucose-lowering therapies and associations with 1-Year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care. 2016; 39 258–63.
| 26681714PubMed |

[12] Butt M, Mhd Ali A, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: a randomised controlled study. Saudi Pharm J. 2016; 24 40–8.
| Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: a randomised controlled study.Crossref | GoogleScholarGoogle Scholar | 26903767PubMed |

[13] Korcegez EI, Sancar M, Demirkan K. Effect of a pharmacist-led program on improving outcomes in patients with Type 2 diabetes Mellitus from Northern Cyprus: a randomized controlled trial. J Manag Care Spec Pharm. 2017; 23 573–82.
| Effect of a pharmacist-led program on improving outcomes in patients with Type 2 diabetes Mellitus from Northern Cyprus: a randomized controlled trial.Crossref | GoogleScholarGoogle Scholar | 28448779PubMed |

[14] Sabate E, editor. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003. [cited 2018 November 16]. Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/.

[15] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353 487–97.
| Adherence to medication.Crossref | GoogleScholarGoogle Scholar | 16079372PubMed |

[16] Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011; 86 304–14.
| Medication adherence: WHO cares?Crossref | GoogleScholarGoogle Scholar | 21389250PubMed |

[17] Robin DiMatteo M, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002; 40 794–811.
| Patient adherence and medical treatment outcomes: a meta-analysis.Crossref | GoogleScholarGoogle Scholar |

[18] Kalogianni A. Factors affect in patient adherence to medication regimen. Health Sci J. 2011; 5 157–8.

[19] Ganguli A, Clewell J, Shillingto AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016; 10 711–25.
| 27175071PubMed |

[20] Pharmaceutical Society of New Zealand Inc. New Zealand National Pharmacist Services Framework 2014. [cited 2017 November 02]. Available from: https://www.psnz.org.nz/Folder?Action=View%20File&Folder_id=86&File=PSNZPharmacistServices 11111Framework2014FINAL.pdf

[21] Tan EC, Stewart K, Elliott RA, George J. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Social Adm Pharm. 2014; 10 608–22.
| Pharmacist services provided in general practice clinics: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 24161491PubMed |

[22] Hatah E, Tordoff J, Duffull SB, et al. Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand. Int J Clin Pharm. 2014; 36 503–12.
| Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand.Crossref | GoogleScholarGoogle Scholar | 24626968PubMed |

[23] Kharjul M, Braund R, Green J. The influence of pharmacist-led adherence support on glycaemic control in people with type 2 diabetes. Int J Clin Pharm. 2018; 40 354–9.
| The influence of pharmacist-led adherence support on glycaemic control in people with type 2 diabetes.Crossref | GoogleScholarGoogle Scholar | 29468528PubMed |

[24] Gavrielov-Yusim N, Friger M. Use of administrative medical databases in population-based research. J Epidemiol Community Health. 2014; 68 283–7.
| Use of administrative medical databases in population-based research.Crossref | GoogleScholarGoogle Scholar | 24248997PubMed |

[25] Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005; 58 323–37.
| A review of uses of health care utilization databases for epidemiologic research on therapeutics.Crossref | GoogleScholarGoogle Scholar | 15862718PubMed |

[26] Cadarette SM, Wong L. An introduction to health care administrative data. Can J Hosp Pharm. 2015; 68 232–7.
| An introduction to health care administrative data.Crossref | GoogleScholarGoogle Scholar | 26157185PubMed |

[27] Rosella LC, Fitzpatrick T, Wodchis WP, et al. High-cost health care users in Ontario, Canada: demographic, socioeconomic, and health status characteristics. BMC Health Serv Res. 2014; 14 532
| High-cost health care users in Ontario, Canada: demographic, socioeconomic, and health status characteristics.Crossref | GoogleScholarGoogle Scholar | 25359294PubMed |

[28] Mazzali C, Paganoni AM, Ieva F, et al. Methodological issues on the use of administrative data in healthcare research: the case of heart failure hospitalizations in Lombardy region, 2000 to 2012. BMC Health Serv Res. 2016; 16 234
| Methodological issues on the use of administrative data in healthcare research: the case of heart failure hospitalizations in Lombardy region, 2000 to 2012.Crossref | GoogleScholarGoogle Scholar | 27391599PubMed |

[29] Lima-Dellamora EDC, Osorio-de-Castro CGS, Madruga LGDSL, Azeredo TB. Use of pharmacy records to measure treatment adherence: a critical review of the literature. Cad Saude Publica. 2017; 33 e00136216
| 28444026PubMed |

[30] Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007; 10 3–12.
| A checklist for medication compliance and persistence studies using retrospective databases.Crossref | GoogleScholarGoogle Scholar | 17261111PubMed |

[31] Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006; 40 1280–8.
| Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.Crossref | GoogleScholarGoogle Scholar | 16868217PubMed |

[32] Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009; 25 2303–10.
| Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.Crossref | GoogleScholarGoogle Scholar | 19635045PubMed |

[33] Chisholm-Burns MA, Spivey CA. The ‘cost’ of medication non-adherence: consequences we cannot afford to accept. J Am Pharm Assoc. 2012; 52 823–6.
| The ‘cost’ of medication non-adherence: consequences we cannot afford to accept.Crossref | GoogleScholarGoogle Scholar |

[34] Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006; 28 1411–24.
| Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization.Crossref | GoogleScholarGoogle Scholar | 17062314PubMed |

[35] Karve S, Cleves MA, Helm M, et al. Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009; 12 989–95.
| Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia.Crossref | GoogleScholarGoogle Scholar | 19402852PubMed |

[36] Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf. 2009; 18 159–65.
| Comparison of various measures for assessing medication refill adherence using prescription data.Crossref | GoogleScholarGoogle Scholar | 19109809PubMed |

[37] Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013; 7 509–16.
| Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis.Crossref | GoogleScholarGoogle Scholar | 23807840PubMed |

[38] Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006; 15 565–74.
| Methods for evaluation of medication adherence and persistence using automated databases.Crossref | GoogleScholarGoogle Scholar | 16514590PubMed |

[39] Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008; 46 1125–33.
| An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.Crossref | GoogleScholarGoogle Scholar | 18953222PubMed |

[40] Zhu VJ, Tu W, Rosenman MB, Overhage JM. A comparison of data driven-based measures of adherence to oral hypoglycemic agents in medicaid patients. AMIA Annu Symp Proc. 2014; 2014 1294–301.
| 25954441PubMed |

[41] Sattler ELP, Lee JS, Perri M. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013; 30 383–99.
| Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature.Crossref | GoogleScholarGoogle Scholar |

[42] Training and Technical Assistance Support Center. Calculating medication adherence for antihypertensive and antidiabetic medications: an evaluation guide for grantees. National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP); 2015. [cited 2018 May 24]. Available from: https://www.cdc.gov/dhdsp/docs/med-adherence-evaluation-tool.pdf.

[43] Jatrana S, Crampton P, Norris P. Ethnic differences in access to prescription medication because of cost in New Zealand. J Epidemiol Community Health. 2011; 65 454–60.
| Ethnic differences in access to prescription medication because of cost in New Zealand.Crossref | GoogleScholarGoogle Scholar | 20466707PubMed |

[44] Norris P, Tordoff J, McIntosh B, et al. Impact of prescription charges on people living in poverty: a qualitative study. Res Social Adm Pharm. 2016; 12 893–902.
| Impact of prescription charges on people living in poverty: a qualitative study.Crossref | GoogleScholarGoogle Scholar | 26681431PubMed |

[45] Assawasuwannakit P, Braund R, Duffull SB. A model-based meta-analysis of the influence of factors that impact adherence to medications. J Clin Pharm Ther. 2015; 40 24–31.
| A model-based meta-analysis of the influence of factors that impact adherence to medications.Crossref | GoogleScholarGoogle Scholar | 25328015PubMed |

[46] Bagge M, Tordoff J, Norris P, Heydon S. Older people’s attitudes towards their regular medicines. J Prim Health Care. 2013; 5 234–42.
| Older people’s attitudes towards their regular medicines.Crossref | GoogleScholarGoogle Scholar | 23998174PubMed |

[47] Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73 691–705.
| A new taxonomy for describing and defining adherence to medications.Crossref | GoogleScholarGoogle Scholar | 22486599PubMed |

[48] Adler AJ, Martin N, Mariani J, et al. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017; 4 CD011851
| 28455948PubMed |

[49] Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017; 4 CD012226
| 28417456PubMed |

[50] van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016; 12 CD004371
| 28000212PubMed |

[51] Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008; CD000011
| 18425859PubMed |

[52] Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014; 11 CD000011

[53] Wishah RA, Al-Khawaldeh OA, Albsoul AM. Impact of pharmaceutical care interventions on glycemic control and other health-related clinical outcomes in patients with type 2 diabetes: randomized controlled trial. Diabetes Metab Syndr. 2015; 9 271–6.
| Impact of pharmaceutical care interventions on glycemic control and other health-related clinical outcomes in patients with type 2 diabetes: randomized controlled trial.Crossref | GoogleScholarGoogle Scholar | 25301007PubMed |

[54] Lim PC, Lim K, Embee ZC, et al. Study investigating the impact of pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. Pak J Pharm Sci. 2016; 29 595–601.
| 27087103PubMed |

[55] Cassimatis M, Kavanagh DJ. Effects of type 2 diabetes behavioural telehealth interventions on glycaemic control and adherence: a systematic review. J Telemed Telecare. 2012; 18 447–50.
| Effects of type 2 diabetes behavioural telehealth interventions on glycaemic control and adherence: a systematic review.Crossref | GoogleScholarGoogle Scholar | 23209266PubMed |

[56] Omran D, Guirguis LM, Simpson SH. Systematic review of pharmacist interventions to improve adherence to oral antidiabetic medications in people with type 2 diabetes. Can J Diab. 2012; 36 292–9.
| Systematic review of pharmacist interventions to improve adherence to oral antidiabetic medications in people with type 2 diabetes.Crossref | GoogleScholarGoogle Scholar |

[57] Jarab AS, Alqudah SG, Mukattash TL. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. J Manag Care Pharm. 2012; 18 516–26.
| Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan.Crossref | GoogleScholarGoogle Scholar | 22971205PubMed |

[58] Odegard PS, Goo A, Hummel J, et al. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005; 39 433–40.
| Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention.Crossref | GoogleScholarGoogle Scholar | 15701763PubMed |

[59] Jacobs M, Sherry PS, Taylor LM, et al. Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. J Am Pharm Assoc. 2012; 52 613–21.
| Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study.Crossref | GoogleScholarGoogle Scholar |